Print Page   |   Contact Us   |   Your Cart   |   Sign In
Search
Sign In
Sign In securely
Breaking News
News & Press: Daily Updates

MMWR: High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Des

Thursday, July 13, 2017   (0 Comments)

Use of eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a 1,000-fold to 2,000-fold increased incidence of meningococcal disease (1). Administration of meningococcal vaccines is recommended for patients receiving eculizumab before beginning treatment (2,3). Sixteen cases of meningococcal disease were identified in eculizumab recipients in the United States during 2008–2016; among these, 11 were caused by nongroupable Neisseria meningitidis

MORE >>


OSAP Disclaimer | Please notify our webmaster of any problems with this website.
OSAP thanks its Super Sponsors for their support in 2017. Sponsorship does not imply endorsement by OSAP of a company's products or services.